Business Standard

Tuesday, December 24, 2024 | 08:55 AM ISTEN Hindi

Notification Icon
userprofile IconSearch

Boosting pharma research

Govt should not solely depend on monetary incentives

Boosting pharma research
Premium

A large drug firm has 12-15 therapy divisions, and if each launches a few drugs, the company brings to the market 30-50 brands a year.

Business Standard Editorial Comment
As reported by this newspaper, the government is in the process of introducing a research-linked incentive (RLI) scheme for the pharmaceutical sector on the lines of the production-linked incentive (PLI) system that has been put into place for several other high-tech or economically important sectors. Details are not publicly available about what this scheme will look like. However, what is known is that the private sector has been consulted on the proposed RLI, and that specific areas within the pharma sector — including antibiotics and biosimilars — will be targets for the scheme.

In broad terms, this scheme is welcome as

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in